WO2012166891A3 - Composés se fixant au récepteur des opioïdes de type mu - Google Patents

Composés se fixant au récepteur des opioïdes de type mu Download PDF

Info

Publication number
WO2012166891A3
WO2012166891A3 PCT/US2012/040168 US2012040168W WO2012166891A3 WO 2012166891 A3 WO2012166891 A3 WO 2012166891A3 US 2012040168 W US2012040168 W US 2012040168W WO 2012166891 A3 WO2012166891 A3 WO 2012166891A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid receptor
compounds
receptor binding
binding compounds
methadone
Prior art date
Application number
PCT/US2012/040168
Other languages
English (en)
Other versions
WO2012166891A2 (fr
Inventor
Luda Diatchenko
William Maixner
Nikolay V. DOKHOLYAN
Feng Ding
Adrian W. R. SEROHIJOS
Shuangye YIN
Original Assignee
Algynomics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algynomics Inc. filed Critical Algynomics Inc.
Publication of WO2012166891A2 publication Critical patent/WO2012166891A2/fr
Publication of WO2012166891A3 publication Critical patent/WO2012166891A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une composition pharmaceutique comprenant (i) un composé modulant le récepteur des opioïdes de type mu choisi dans le groupe constitué par les composés du groupe I, les composés apparentés et leurs dérivés pharmaceutiquement acceptables, (ii) un véhicule pharmaceutiquement acceptable et (iii) éventuellement, un autre agent thérapeutique. L'invention porte également sur des méthodes thérapeutiques d'administration de composés modulant le récepteur des opioïdes de type mu et sur des formulations cocktails avec d'autres composés se fixant au récepteur des opioïdes de type mu, par exemple la morphine, la (+)-morphine, la méthadone, la (+)-méthadone, la 3-méthoxynaltrexone, l'étorphine ou la naltrexone.
PCT/US2012/040168 2011-05-31 2012-05-31 Composés se fixant au récepteur des opioïdes de type mu WO2012166891A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161491828P 2011-05-31 2011-05-31
US61/491,828 2011-05-31

Publications (2)

Publication Number Publication Date
WO2012166891A2 WO2012166891A2 (fr) 2012-12-06
WO2012166891A3 true WO2012166891A3 (fr) 2013-03-28

Family

ID=47260314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/040168 WO2012166891A2 (fr) 2011-05-31 2012-05-31 Composés se fixant au récepteur des opioïdes de type mu

Country Status (1)

Country Link
WO (1) WO2012166891A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049500A1 (fr) 2014-09-25 2016-03-31 Duke University Inhibiteurs de kinases et méthodes d'utilisation associées
EP3458061B1 (fr) 2016-05-19 2023-01-18 Virginia Commonwealth University Modulateurs puissants et sélectifs des récepteurs opioïdes mu
MA51610A (fr) * 2018-01-15 2021-04-21 UCB Biopharma SRL Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
WO2021007366A1 (fr) * 2019-07-08 2021-01-14 St. Louis College Of Pharmacy Agonistes/analgésiques au récepteur opioïde à polarisation de protéine g à recrutement d'arrestine réduit
WO2022182395A1 (fr) * 2021-02-26 2022-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibiteurs à petites molécules de domaine n-terminal de stat3 et méthodes d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US20080176884A1 (en) * 2006-11-22 2008-07-24 Progenics Pharmaceuticals, Inc. 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US20080176884A1 (en) * 2006-11-22 2008-07-24 Progenics Pharmaceuticals, Inc. 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIMMO INGMAN ET AL.: "Prolonged Central mu-Opioid Receptor Occupancy after Single and Repeated Nalmefene Dosing", NEUROPSYCHOPHARMACOLOGY, vol. 30, no. 12, 2005, pages 2245 - 2253 *
PAVEL GIRLS ET AL.: "A novel alternatively spliced isoform of the mu- opioid receptor: functional antagonism", MOLECULAR PAIN, vol. 6, no. 33, 2010, pages 1 - 10 *

Also Published As

Publication number Publication date
WO2012166891A2 (fr) 2012-12-06

Similar Documents

Publication Publication Date Title
WO2009085990A3 (fr) Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci
IL248246B (en) (5r,2s)-6-(benzyloxy/allyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylates, process for their preparation and use of (5r,2s)-tert-butyl-6 -(benzyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylate for the preparation of anti-infective drugs
IL244974A0 (en) Preparations in flat form containing buprenorphine and naloxone, formulations in flat form containing them, and their use in the preparation of drugs for the treatment of narcotic dependence
WO2009106831A3 (fr) Composition pharmaceutique
HK1200373A1 (en) Transdermal therapeutic system for administering the active substance buprenorphine
WO2007148208A3 (fr) Nouveau (aza) cyclohexanes carbonylés comme ligands récepteurs de la dopamine d3
WO2011157721A3 (fr) Composition pharmaceutique contenant de l'ivabradine
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2010108154A3 (fr) Inhibiteurs peptidiques de kv1.3 sélectifs et puissants
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
WO2009006590A3 (fr) Procédés de préparation de docétaxel et de polymorphes
IL219602A (en) Tricyclic compounds containing pyrazole, a process for their preparation and their pharmaceutical compositions
WO2008096001A8 (fr) Phénylcarbamates macrocycliques inhibant le virus de l'hépatite c (vhc)
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2010070449A3 (fr) Laquinimode très pur ou sel pharmaceutiquement acceptable de celui-ci
WO2013004995A8 (fr) Composés pyrimidinones et leur utilisation
WO2013055689A8 (fr) R(+)-n-méthyl-propargyl-aminoindane
WO2012166891A3 (fr) Composés se fixant au récepteur des opioïdes de type mu
WO2008120080A3 (fr) Procédé amélioré de synthèse de solifénacine
WO2009140341A3 (fr) Compositions d'atorvastatine
WO2011141488A3 (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
EP4349369A3 (fr) Augmentation de la biodisponibilité de médicaments dans une thérapie par naltrexone
EP2238105A4 (fr) Nouveaux composés, isomère ou sels pharmaceutiquement acceptables de ces derniers, utilisés comme antagonistes du récepteur vanilloïde, et compositions pharmaceutiques les contenant
WO2013169746A3 (fr) N-ethyl-4-hydroxyl-1-méthyl-5-(méthyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phényl-1,2-dihydroquinoléine-3-carboxamide
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12793391

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12793391

Country of ref document: EP

Kind code of ref document: A2